Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Halozyme Therapeutics
Pharma
Enhertu, Akeso, Fujifilm-Regeneron—Fierce Pharma Asia
Enhertu delivered a positive readout in first-line breast cancer. Akeso's ivonescimab bagged another phase 3 win. Fujifilm signed a 10-year deal with Regeneron.
Angus Liu
Apr 25, 2025 8:45am
Halozyme sues Merck over subcutaneous Keytruda
Apr 24, 2025 2:41pm
FDA approves BMS' subcutaneous Opdivo with some limitations
Jan 2, 2025 9:15am
Argenx adds 4 new targets to Halozyme collab for $30M
Oct 3, 2024 10:54am
Roche's subcutaneous Tecentriq wins FDA nod after delay
Sep 13, 2024 11:41am
Arbitrator sides with J&J, upholding Darzalex ruling vs. Genmab
Jan 23, 2024 10:23am
